MedTrace Logo

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

NCT00901745 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-08-10

No results posted yet for this study

Summary

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.

Conditions

Interventions

DRUG

Angiotensin II

Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.

DRUG

Noradrenaline infusion

Infusion of up to 480 picomol/ml of noradrenaline will be infused.

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Gareth D Barnes, MBChB · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901745 on ClinicalTrials.gov